HOME >> MEDICINE >> NEWS
Pioglitazone HCI shown to lower blood pressure in hypertensive patients with type 2 diabetes

Orlando FL, June 5, 2004 Type 2 diabetes and hypertension are commonly associated conditions, both of which carry an increased risk of cardiovascular disease. Results of a large, open-label, multi-center, observational clinical trial show that treatment with the oral anti-diabetic agent pioglitazone HCl in people with type 2 diabetes has beneficial effects in reducing hypertension. The findings were presented today at the American Diabetes Association's 64th Annual Scientific Sessions.

In a study of 3,140 hypertensive patients with type 2 diabetes, all patients received open-label pioglitazone (30 mg/day) for 16 weeks. Hypertension was classified according to current National Institutes of Health guidelines (JNC VII): Stage I: 140-159/90-99 mmHg; Stage II: >160/>100 mmHg. Among patients with Stage I hypertension, pioglitazone elicited a mean decrease of 6.9/3.1 mmHg compared to baseline. In the patients with more severe, Stage II hypertension, pioglitazone was associated with a decrease of 18.7/8.3 mmHg.

"Although increasing clinical evidence suggests that drugs such as pioglitazone have blood pressure lowering effects, until now, those results had not been confirmed in large, unselected patient populations," noted lead investigator Thomas Konrad, M.D., Ass.Prof. Institute for Metabolic Research, Frankfurt, EU RISC- Study Center. "The importance of treating hypertension in patients with type 2 diabetes is particularly crucial because of the high incidence of elevated blood pressure in people with diabetes. A major government study found that almost 80 percent of patients with diabetes also have hypertension, thereby compounding their cardiovascular disease risk. These blood pressure-lowering findings are remarkable, because they suggest that pioglitazone may be able to impact certain cardiovascular disease risk factors in patients with type 2 diabetes."

In patients with type 2 diabetes, management of risk factors beyond diabetes
'"/>

Contact: Julio Cantre
julio.cantre@ketchum.com
646-935-4122
Ketchum
6-Jun-2004


Page: 1 2

Related medicine news :

1. Pioglitazone shown to reverse thickening of carotid artery wall
2. Cartilage repair techniques shown to restore patient mobility and reduce pain
3. Sprinklers shown effective in slowing dorm fires
4. Controversial drug shown to act on brain protein to cut alcohol use
5. HPV vaccine shown effective at reducing cancer-causing infections
6. HPV vaccine shown to substantially reduce cervical cancer
7. New research results: Heart jacket shown to be effective
8. Isolated soy protein shown to benefit type 2 diabetics, study indicates
9. Increased risk of cardiovascular disease shown in PCOS patients
10. Combination therapy w/ ACTOS (pioglitazone HCI) shown to improve components of diabetic dyslipidemia
11. Anti-eosinophil therapy shown to be effective in treating hypereosinophilic syndrome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
Breaking Medicine Technology:
Cached News: